Nektar Therapeutics to Present Promising Phase 2b Results for Rezpegaldesleukin in Atopic Dermatitis at EADV 2025 Congress

Reuters

2025/09/09

Nektar <a href="https://laohu8.com/S/LENZ">Therapeutics</a> to Present Promising Phase 2b Results for Rezpegaldesleukin in Atopic Dermatitis at EADV 2025 Congress

Nektar Therapeutics has announced that it will present the results from its ongoing REZOLVE-AD Phase 2b study at the upcoming 2025 European Academy of Dermatology and Venereology (EADV) Congress in Paris, France, from September 17-20, 2025. The study investigates the efficacy and safety of Rezpegaldesleukin, a selective regulatory T-cell-inducing interleukin-2 conjugate, in treating atopic dermatitis. The presentation, scheduled for September 18, will cover findings from the 16-week induction phase, including primary and secondary endpoints and patient-reported outcomes. Additional data will be shared on patients who transitioned from placebo to high dose treatment. The presentation will be available on Nektar's website following the event.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nektar Therapeutics published the original content used to generate this news brief via PR Newswire (Ref. ID: SF68289) on September 09, 2025, and is solely responsible for the information contained therein.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2566699161"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2566699161\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2566699161?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-09-09 19:03","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2566699161","market":"nz","top_or_hot":-1,"title":"Nektar Therapeutics to Present Promising Phase 2b Results for Rezpegaldesleukin in Atopic Dermatitis at EADV 2025 Congress","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Nektar <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> to Present Promising Phase 2b Results for Rezpegaldesleukin in Atopic Dermatitis at EADV 2025 Congress\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Nektar Therapeutics has announced that it will present the results from its ongoing REZOLVE-AD Phase 2b study at the upcoming 2025 European Academy of Dermatology and Venereology (EADV) Congress in Paris, France, from September 17-20, 2025. The study investigates the efficacy and safety of Rezpegaldesleukin, a selective regulatory T-cell-inducing interleukin-2 conjugate, in treating atopic dermatitis. The presentation, scheduled for September 18, will cover findings from the 16-week induction phase, including primary and secondary endpoints and patient-reported outcomes. Additional data will be shared on patients who transitioned from placebo to high dose treatment. The presentation will be available on Nektar's website following the event.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nektar Therapeutics published the original content used to generate this news brief via PR Newswire (Ref. ID: SF68289) on September 09, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Nektar Therapeutics to Present Promising Phase 2b Results for Rezpegaldesleukin in Atopic Dermatitis at EADV 2025 Congress</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNektar Therapeutics to Present Promising Phase 2b Results for Rezpegaldesleukin in Atopic Dermatitis at EADV 2025 Congress\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-09-09 19:03</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Nektar <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> to Present Promising Phase 2b Results for Rezpegaldesleukin in Atopic Dermatitis at EADV 2025 Congress\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Nektar Therapeutics has announced that it will present the results from its ongoing REZOLVE-AD Phase 2b study at the upcoming 2025 European Academy of Dermatology and Venereology (EADV) Congress in Paris, France, from September 17-20, 2025. The study investigates the efficacy and safety of Rezpegaldesleukin, a selective regulatory T-cell-inducing interleukin-2 conjugate, in treating atopic dermatitis. The presentation, scheduled for September 18, will cover findings from the 16-week induction phase, including primary and secondary endpoints and patient-reported outcomes. Additional data will be shared on patients who transitioned from placebo to high dose treatment. The presentation will be available on Nektar's website following the event.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nektar Therapeutics published the original content used to generate this news brief via PR Newswire (Ref. ID: SF68289) on September 09, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"製藥","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250909:nNDLXytx1:1","article_id":"2566699161","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2566699161","pubTimestamp":1757415788,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Nektar Therapeutics has announced that it will present the results from its ongoing REZOLVE-AD Phase 2b study at the upcoming 2025 European Academy of Dermatology and Venereology  Congress in Paris, France, from September 17-20, 2025. The study investigates the efficacy and safety of Rezpegaldesleukin, a selective regulatory T-cell-inducing interleukin-2 conjugate, in treating atopic dermatitis. The presentation, scheduled for September 18, will cover findings from the 16-week induction phase, including primary and secondary endpoints and patient-reported outcomes. Additional data will be shared on patients who transitioned from placebo to high dose treatment. The presentation will be available on Nektar's website following the event.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpre","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药","NKTR":"内克塔治疗"},"translate_title":"Nektar Therapeutics将在EADV 2025大会上展示Rezpegaldesleukin治疗特应性皮炎的有希望的2b期结果","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NKTR":0.9},"content_text":"Nektar Therapeutics to Present Promising Phase 2b Results for Rezpegaldesleukin in Atopic Dermatitis at EADV 2025 Congress\n    \n\n        Nektar Therapeutics has announced that it will present the results from its ongoing REZOLVE-AD Phase 2b study at the upcoming 2025 European Academy of Dermatology and Venereology (EADV) Congress in Paris, France, from September 17-20, 2025. The study investigates the efficacy and safety of Rezpegaldesleukin, a selective regulatory T-cell-inducing interleukin-2 conjugate, in treating atopic dermatitis. The presentation, scheduled for September 18, will cover findings from the 16-week induction phase, including primary and secondary endpoints and patient-reported outcomes. Additional data will be shared on patients who transitioned from placebo to high dose treatment. The presentation will be available on Nektar's website following the event.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nektar Therapeutics published the original content used to generate this news brief via PR Newswire (Ref. ID: SF68289) on September 09, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}